W. Dornoff

Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.

M. Lichinitser, J. Body, E. Kreuser, 2004, European journal of cancer.

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.

A. Hasenburg, D. Kieback, W. Dornoff, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.

R. Stahel, S. Ricci, J. von Pawel, 1999, Lung cancer.

Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.

R. Stahel, S. Ricci, P. Kellokumpu-Lehtinen, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.

S. Ricci, J. von Pawel, P. Kellokumpu-Lehtinen, 1997, Seminars in oncology.

Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: A prospective multicenter study

C. Meisner, T. Wiegel, M. Hartmann, 1997 .

Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study.

C. Meisner, T. Wiegel, M. Hartmann, 1998, International journal of radiation oncology, biology, physics.

Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy.

M. Engelhard, G. Brittinger, H. Gerhartz, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.

M. Lichinitser, J. Body, E. Kreuser, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

The Anti-Emetic Efficiacy of Intravenous Dolasetron Mesilate plus Dexamethasone versus Intravenous Dolasetron Mesilate Alone in Patients Receiving Fractionated Chemotherapy

W. Dornoff, J. Nowicki, A. Fauser, 1999, Oncology Research and Treatment.